TY - JOUR
KW - Alcohol-Related Disorders/drug therapy
KW - Humans
KW - Naltrexone/administration & dosage
KW - Opioid-Related Disorders/drug therapy
KW - Substance Abuse Treatment Centers/statistics & numerical data
KW - United States
AU - L. Aletraris
AU - Bond Edmond
AU - P. M. Roman
A1 - 
AB - OBJECTIVE: Medication-assisted treatment for substance use disorders (SUDs) is not widely used in treatment programs. The aims of the current study were to document the prevalence of adoption and implementation of extended-release injectable naltrexone, the newest U.S. Food and Drug Administration-approved medication for alcohol use disorder (AUD), in U.S. treatment programs and to examine associations between organizational and patient characteristics and adoption. METHOD: The study used interview data from a nationally representative sample of 307 U.S. SUD treatment programs to examine adoption and implementation of injectable naltrexone. RESULTS: Thirteen percent of programs used injectable naltrexone for AUD, and 3% of programs used it for opioid use disorder. Every treatment program that offered injectable naltrexone to its patients used it in conjunction with psychosocial treatment, particularly cognitive behavioral therapy. Multivariate logistic regression results indicated that adoption was positively associated with the provision of wraparound services, the percentage of privately insured patients, and the presence of inpatient detoxification services. For-profit status and offering inpatient services were negatively associated with adoption. Within adopting programs, an average of 4.1% of AUD patients and 7.1% of patients with opioid use disorder were currently receiving the medication, despite clinical directors' reports of positive patient outcomes, particularly for relapsers and for those who had been noncompliant with other medications. Cost was a significant issue for the majority of adopting organizations. CONCLUSIONS: The rate of adoption of injectable naltrexone in U.S. treatment programs remains limited. Researchers should continue to examine patient, organizational, and external characteristics associated with the adoption and implementation of injectable naltrexone over time.
BT - Journal of studies on alcohol and drugs
C5 - Opioids & Substance Use; Financing & Sustainability
CP - 1
CY - United States
IS - 1
JF - Journal of studies on alcohol and drugs
N2 - OBJECTIVE: Medication-assisted treatment for substance use disorders (SUDs) is not widely used in treatment programs. The aims of the current study were to document the prevalence of adoption and implementation of extended-release injectable naltrexone, the newest U.S. Food and Drug Administration-approved medication for alcohol use disorder (AUD), in U.S. treatment programs and to examine associations between organizational and patient characteristics and adoption. METHOD: The study used interview data from a nationally representative sample of 307 U.S. SUD treatment programs to examine adoption and implementation of injectable naltrexone. RESULTS: Thirteen percent of programs used injectable naltrexone for AUD, and 3% of programs used it for opioid use disorder. Every treatment program that offered injectable naltrexone to its patients used it in conjunction with psychosocial treatment, particularly cognitive behavioral therapy. Multivariate logistic regression results indicated that adoption was positively associated with the provision of wraparound services, the percentage of privately insured patients, and the presence of inpatient detoxification services. For-profit status and offering inpatient services were negatively associated with adoption. Within adopting programs, an average of 4.1% of AUD patients and 7.1% of patients with opioid use disorder were currently receiving the medication, despite clinical directors' reports of positive patient outcomes, particularly for relapsers and for those who had been noncompliant with other medications. Cost was a significant issue for the majority of adopting organizations. CONCLUSIONS: The rate of adoption of injectable naltrexone in U.S. treatment programs remains limited. Researchers should continue to examine patient, organizational, and external characteristics associated with the adoption and implementation of injectable naltrexone over time.
PP - United States
PY - 2015
SN - 1938-4114; 1937-1888
SP - 143
EP - 151
EP - 
T1 - Adoption of injectable naltrexone in U.S. substance use disorder treatment programs
T2 - Journal of studies on alcohol and drugs
TI - Adoption of injectable naltrexone in U.S. substance use disorder treatment programs
U1 - Opioids & Substance Use; Financing & Sustainability
U2 - 25486403
VL - 76
VO - 1938-4114; 1937-1888
Y1 - 2015
ER -